These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 17308886)

  • 1. Glycogen storage disease types I and II: treatment updates.
    Koeberl DD; Kishnani PS; Chen YT
    J Inherit Metab Dis; 2007 Apr; 30(2):159-64. PubMed ID: 17308886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.
    Sun B; Zhang H; Franco LM; Young SP; Schneider A; Bird A; Amalfitano A; Chen YT; Koeberl DD
    Mol Ther; 2005 Jan; 11(1):57-65. PubMed ID: 15585406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Development of New Therapy for Glycogen Storage Diseases.
    Sun B; Brooks ED; Koeberl DD
    Curr Gene Ther; 2015; 15(4):338-47. PubMed ID: 26122079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy.
    Brooks ED; Landau DJ; Everitt JI; Brown TT; Grady KM; Waskowicz L; Bass CR; D'Angelo J; Asfaw YG; Williams K; Kishnani PS; Koeberl DD
    J Inherit Metab Dis; 2018 Nov; 41(6):965-976. PubMed ID: 30043186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy for glycogen storage diseases.
    Koeberl DD; Koch RL; Lim JA; Brooks ED; Arnson BD; Sun B; Kishnani PS
    J Inherit Metab Dis; 2024 Jan; 47(1):93-118. PubMed ID: 37421310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alglucosidase alfa therapy for Pompe disease in pregnancy - Case report.
    Kłos J; Kwaśniak-Butowska M; Sławek J
    J Neurol Sci; 2017 Apr; 375():167-169. PubMed ID: 28320122
    [No Abstract]   [Full Text] [Related]  

  • 7. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
    Kishnani PS; Beckemeyer AA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
    Han SO; Li S; Bird A; Koeberl D
    Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normoglycemia alone is insufficient to prevent long-term complications of hepatocellular adenoma in glycogen storage disease type Ib mice.
    Yiu WH; Pan CJ; Mead PA; Starost MF; Mansfield BC; Chou JY
    J Hepatol; 2009 Nov; 51(5):909-17. PubMed ID: 19376605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
    Xu F; Ding E; Migone F; Serra D; Schneider A; Chen YT; Amalfitano A
    J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
    Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A
    Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.
    Franco LM; Sun B; Yang X; Bird A; Zhang H; Schneider A; Brown T; Young SP; Clay TM; Amalfitano A; Chen YT; Koeberl DD
    Mol Ther; 2005 Nov; 12(5):876-84. PubMed ID: 16005263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia.
    Koeberl DD; Pinto C; Sun B; Li S; Kozink DM; Benjamin DK; Demaster AK; Kruse MA; Vaughn V; Hillman S; Bird A; Jackson M; Brown T; Kishnani PS; Chen YT
    Mol Ther; 2008 Apr; 16(4):665-72. PubMed ID: 18362924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer.
    Ghosh A; Allamarvdasht M; Pan CJ; Sun MS; Mansfield BC; Byrne BJ; Chou JY
    Gene Ther; 2006 Feb; 13(4):321-9. PubMed ID: 16195703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pompe disease: early diagnosis and early treatment make a difference.
    Chien YH; Hwu WL; Lee NC
    Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fractures in children with Pompe disease: a potential long-term complication.
    Case LE; Hanna R; Frush DP; Krishnamurthy V; DeArmey S; Mackey J; Boney A; Morgan C; Corzo D; Bouchard S; Weber TJ; Chen YT; Kishnani PS
    Pediatr Radiol; 2007 May; 37(5):437-45. PubMed ID: 17342521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.
    Lacaná E; Yao LP; Pariser AR; Rosenberg AS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
    Prescrire Int; 2007 Dec; 16(92):240-1. PubMed ID: 18092404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nutrition therapy for hepatic glycogen storage diseases.
    Goldberg T; Slonim AE
    J Am Diet Assoc; 1993 Dec; 93(12):1423-30. PubMed ID: 8245377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach.
    Ing RJ; Cook DR; Bengur RA; Williams EA; Eck J; Dear Gde L; Ross AK; Kern FH; Kishnani PS
    Paediatr Anaesth; 2004 Jun; 14(6):514-9. PubMed ID: 15153218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.